Bio-Rad Laboratories (FRA:BUWA) EPS without NRI: €7.65 (TTM As of Mar. 2026)


FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
71 GF Score
Price €259.60
GF Value €278.74
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories EPS without NRI?

Bio-Rad Laboratories FRA:BUWA +0.39% 71 EPS without NRI is €7.65 as of Mar. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 71/100 and a GF Value™ of €278.74 (Fairly Valued). The stock has 5 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks worse than 74.47% on this metric.

Bio-Rad Laboratories's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €1.64. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €7.65.

During the past 12 months, Bio-Rad Laboratories's average earnings per share (NRI) Growth Rate was -4.80% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -11.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -4.90% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Bio-Rad Laboratories's EPS without NRI or its related term are showing as below:

FRA:BUWA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.3   Med: 10.5   Max: 186.1
Current: -11.7

During the past 13 years, Bio-Rad Laboratories's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 186.10% per year. The lowest was -53.30% per year. And the median was 10.50% per year.

FRA:BUWA's 3-Year EPS without NRI Growth Rate is ranked worse than
74.47% of 662 companies
in the Medical Devices & Instruments industry
Industry Median: 8.15 vs FRA:BUWA: -11.70

Bio-Rad Laboratories's EPS (Diluted) for the three months ended in Mar. 2026 was €-16.91. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.15.

Bio-Rad Laboratories's EPS (Basic) for the three months ended in Mar. 2026 was €-16.91. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.18.


Bio-Rad Laboratories  (FRA:BUWA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bio-Rad Laboratories EPS without NRI Related Terms


Bio-Rad Laboratories EPS without NRI Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories EPS without NRI Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.86 13.61 10.80 9.85 8.47

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 1.95 1.93 2.14 1.64

FRA:BUWA vs GKOS, BRKR, PODD: EPS without NRI Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's PE Ratio without NRI falls into.


FRA:BUWA
71GF Score
Bio-Rad Laboratories Inc FRA:BUWA
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €7.65 mean?
Bio-Rad Laboratories (FRA:BUWA) has a EPS without NRI of €7.65 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bio-Rad Laboratories and its competitors. According to the industry distribution chart, Bio-Rad Laboratories ranks #493 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 74.5%.
Is Bio-Rad Laboratories' EPS without NRI too high?
Bio-Rad Laboratories' current EPS without NRI is €7.65. Based on the distribution chart, Bio-Rad Laboratories ranks #493 out of 662 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' EPS without NRI compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #493 out of 662 companies for EPS without NRI. This places Bio-Rad Laboratories in the lower half of its industry. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current EPS without NRI is €7.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €278.74, compared to a current price of €259.60 — trading 6.9% below its estimated fair value. The current EPS without NRI is €7.65. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current EPS without NRI is €7.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €259.60 is trading 6.9% below its estimated GF Value™ of €278.74. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • EPS without NRI: €7.65
  • GF Value™: €278.74 vs. price of €259.60 (6.9% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for FRA:BUWA

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€259.60
Price
€278.74
GF Value